February 1983 States Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 020618-000600US
Client Reference No.: N9-59

6mmissioner for Patents

O. Box 1450 Alexandria, VA 22313-1450

On July 30, 2003

TOWNSEND and TOWNSEND and CREW LLP

Nicole M. Burke

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Gregory S. Hageman

Application No.: 09/511,008

Filed: February 22, 2000

For: DIAGNOSTICS AND

THERAPEUTICS FOR ARTERIAL WALL DISRUPTIVE DISORDERS

Group Director: 1632

Examiner: Q. Janice Li

Art Unit: 1632

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37

CFR §1.97 and §1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

Gregory S. Hageman

Application No.: 09/511,008

Page 2

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that <u>no fee is required</u> for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Scott L. Ausenhus Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834

Tel: 303-571-4000 Fax: 303-571-4321

SLA:nmb

DE 7111773 v1

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

TRAD Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Kn wn **Application Number** 09/511,008 **Filing Date** February 22, 2000 First Named Inventor Art Unit 1632 **Examiner Name** Q. Janice Li

(use as many sheets as necessary)

Page of Attorney Docket Number 020618-000600US

U.S. PATENT DOCUMENTS					
		Document Number			
Examiner	Cite No.1	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	US-			
	2	US-			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or	Pages, Columns, Lines,		
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶
	B1						}	
	B2							

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2		
	C1	BOBRYSHEV, Y.V. et al. "Immunophenotypic analysis of the aortic aneurysm wall suggests that vascular dendritic cells are involved in immune responses", <i>Cardiovascular Surgery</i> , 1998, pp. 240-249, Vol. 6, No. 3, Published by Elsevier Science Ltd. in Great Britain.			
	C2				

	 	
Examiner	Date	
Signature	Considered	
Olgitataro	00110100100	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 6 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.